Bio-Techne Corp Common Stock
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
TECH Overview
Sector |
Health Care |
Industry |
Biotechnology: Biological Products (No Diagnostic Substances) |
Previous Close |
$89.4200 |
Previous Close Volume |
1610000 |
Latest News
- BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 20 Dec 2024 07:03:21
- BIO-TECHNE ANNOUNCES BIOTHERAPEUTIC CHARACTERIZATION STRATEGIC CO-MARKETING AND CO-PROMOTION AGREEMENT 19 Dec 2024 07:02:03
- ScaleReady awards a G-Rex® Grant to Moonlight Bio 18 Dec 2024 07:03:08
- BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH MEDSANTEK TO EXPAND ACCESS TO PORTFOLIO ACROSS TURKEY 12 Dec 2024 07:02:00
- BIO-TECHNE LAUNCHES ESR1 MUTATION MONITORING ASSAY 10 Dec 2024 07:05:25
- BIO-TECHNE TO PRESENT AT THE CITI 2024 GLOBAL HEALTHCARE CONFERENCE 27 Nov 2024 07:06:36
- BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES 20 Nov 2024 07:06:25
- BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH 18 Nov 2024 07:06:52
- BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO 14 Nov 2024 07:05:57
- BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS 11 Nov 2024 07:06:44
- BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES 08 Nov 2024 07:04:15
- BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING 06 Nov 2024 07:04:44
- LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH 05 Nov 2024 07:04:41
- BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS 30 Oct 2024 06:34:37
- ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics 29 Oct 2024 07:05:10
- BIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 30, 2024, TO ANNOUNCE FIRST QUARTER FISCAL 2025 FINANCIAL RESULTS 10 Oct 2024 07:06:49
- ScaleReady announces a G-Rex® Grant has been awarded to LIfT Biosciences 09 Oct 2024 07:06:56
- ScaleReady announces a G-Rex® Grant has been awarded to Dr. Eric Tran of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute 08 Oct 2024 07:06:48
- ScaleReady announces a G-Rex® Grant has been awarded to renowned cancer immunologist Dr. Christopher A. Klebanoff 07 Oct 2024 07:06:51
- LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH 26 Sep 2024 07:05:55
- BIO-TECHNE TO PRESENT AT NEUROSCIENCE 2024-THE SOCIETY FOR NEUROSCIENCE (SfN) ANNUAL MEETING 24 Sep 2024 07:04:49
- ScaleReady announces a G-Rex® Grant has been awarded to ImmunoScape 18 Sep 2024 07:04:36
- ScaleReady announces a G-Rex® Grant has been awarded to Verismo Therapeutics 17 Sep 2024 07:04:40
- ScaleReady and Bio-Techne Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex® Manufacture of CAR-T and TCR Therapies 16 Sep 2024 07:04:43
- ScaleReady announces the inaugural G-Rex® Grant has been awarded to Stanford Medicine Laboratory for Cell and Gene Medicine 27 Aug 2024 07:06:04
- BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES 26 Aug 2024 07:06:29
- BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS 07 Aug 2024 06:37:35
- BIO-TECHNE ANNOUNCES NEXT-GENERATION HIGH THROUGHPUT SIMPLE WESTERN SYSTEM 31 Jul 2024 07:22:46
- BIO-TECHNE ANNOUNCES STRATEGIC INVESTMENT IN SPEAR BIO 29 Jul 2024 07:22:54
- BIO-TECHNE TO HOST CONFERENCE CALL ON AUGUST 7, 2024, TO ANNOUNCE FOURTH QUARTER AND FISCAL 2024 FINANCIAL RESULTS 15 Jul 2024 07:22:41
- BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES 31 May 2024 07:08:17
- BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE 30 May 2024 07:08:10
- ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing 29 May 2024 07:07:03
- BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE 23 May 2024 07:23:33
- BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024 08 May 2024 07:23:45
- BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) 07 May 2024 07:23:09
- BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2024 RESULTS 01 May 2024 06:53:26
- BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS 30 Apr 2024 07:23:53
- BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH THERMO FISHER SCIENTIFIC 29 Apr 2024 07:08:56
- BIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY 26 Apr 2024 07:08:38
- BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS 23 Apr 2024 07:08:25
- BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS 10 Apr 2024 07:23:47
- BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY 08 Apr 2024 07:23:48
- BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE 03 Apr 2024 07:08:47
- BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE SPATIAL BIOLOGY SERVICES 28 Mar 2024 09:24:12
- BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC MYELOID LEUKEMIA 22 Mar 2024 07:24:14
- BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM 12 Mar 2024 07:24:07
- BIO-TECHNE TO PRESENT AT THE BARCLAYS 26th ANNUAL GLOBAL HEALTHCARE CONFERENCE 06 Mar 2024 07:23:54
-
BIO-TECHNE DECLARES DIVIDEND
01 Feb 2024 06:54:13
https://investors.bio-techne.com/press-releases/detail/406/bio-techne-declares-dividend
- LUNAPHORE AND ACD REVOLUTIONIZE SPATIAL BIOLOGY RESEARCH WITH THE LAUNCH OF THE FIRST FULLY AUTOMATED, SAME-SECTION, HYPERPLEX MULTIOMICS APPLICATION 25 Jan 2024 07:09:19
- SCIENTISTS AT THE WCBP CONFERENCE HIGHLIGHT ADVANCEMENTS IN PROTEIN BIOTHERAPEUTIC CHARGE HETEROGENEITY CHARACTERIZATION USING THE MauriceFlex™ SYSTEM 24 Jan 2024 07:09:24
- BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2024, TO ANNOUNCE SECOND QUARTER FISCAL 2024 FINANCIAL RESULTS 16 Jan 2024 07:09:19